Publications Show Reductions in Hospital
Resource Utilization Associated with 10 kHz
Therapy Spinal Cord Stimulation for the Treatment of
Painful Diabetic Neuropathy and Nonsurgical Refractory Back
Pain
REDWOOD
CITY, Calif., Sept. 18,
2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a
global medical device company that is delivering comprehensive,
life-changing solutions for the treatment of chronic pain, today
announced the publication of new data validating the health
economic benefits of 10 kHz Therapy™, Nevro's proprietary
high-frequency,10 kHz spinal cord stimulation (SCS) therapy. This
data was derived from studies and analyses that evaluated health
care utilization (HCU) – doctor visits, medical procedures, tests
and emergency room visits, and medication costs – and related cost
data, including inpatient and outpatient service, medication, and
out-of-pocket costs.
Results from a study evaluating the effect of 10 kHz Therapy on
resources needed to manage and care for patients with painful
diabetic neuropathy (PDN) were published in the Journal of
Managed Care & Specialty Pharmacy. Study participants were
randomly assigned to 10 kHz Therapy or conventional medical
management (CMM), with outcomes measured at six months. Results
showed that the 10 kHz Therapy arm experienced about half the mean
rate of hospitalizations per patient compared to the CMM group
(0.08 vs. 0.15). Additionally, the CMM group's total healthcare
costs per patient were approximately 51 percent higher compared to
the 10 kHz Therapy group (equivalent to a mean annual cost per
patient of $9,532 vs. $6,300).
"This new research underscores the financial and resource cost
of treating patients with PDN – a patient population that has long
gone without effective treatment options provided by today's
standard of care," said David
Caraway, MD, chief medical officer at Nevro. "I am grateful
to the study researchers, who have provided managed care
organizations with real-world data to help improve the treatment
options available for patients with refractory PDN."
This latest publication comes on the heels of other recent
studies, which add to the robust body of evidence to support 10 kHz
Therapy for the treatment of both PDN and chronic nonsurgical back
pain.
Cost-Effectiveness of 10 kHz Therapy for Nonsurgical
Refractory Back Pain (NSRBP)
This analysis, published
in the Journal of Neurosurgery: Spine,
evaluated whether 10 kHz Therapy plus CMM is
cost-effective compared to CMM alone for patients with
chronic, refractory back pain who are not candidates for
surgery. Nevro's NSRBP study is the first randomized
controlled trial in the U.S. to prospectively gather HCU
data to evaluate the cost-effectiveness of any type of
SCS therapy to treat patients with nonsurgical back pain.
This analysis showed that 10 kHz Therapy provides a higher quality
of life (QOL) at a lower average cost per patient
compared to CMM therapy and is predicted to be
cost-effective for the treatment of nonsurgical back pain compared
with CMM within 2.1 years.
Healthcare Resource Utilization of 10 kHz Therapy for Chronic
Refractory Low Back Pain
This analysis, published in
Neuromodulation, evaluated the cost burden of 10 kHz Therapy
in patients with Chronic Refractory Low Back Pain (CRLBP). Using
IBM MarketScan databases, investigators retrospectively identified
patients who received 10 kHz Therapy between 2016 and 2019. Those
with low back pain who had no history of surgery were included in
the cohort. Cost data were collected six months before implantation
and one, three, and six months after implantation. In the six
months before receiving 10 kHz Therapy, patients incurred median
total costs of $15,766, whereas, in
the six months post-implantation, the median total cost, excluding
device acquisition, was $5,840.
Median out-of-pocket costs for patients decreased by nearly
$900 in the first six months
post-implant. The average reduction in total cost was $6,914 (95% CI: $588, $12,458, p
< 0.001). Investigators found that 10 kHz Therapy may be
associated with a significant decrease in total healthcare costs,
offsetting device acquisition costs within 27 months.
Healthcare Economics of High-Frequency SCS for
PDN
Data published in the Journal of Diabetes Science and
Technology evaluated HCU data of 10 kHz Therapy on a real-world
PDN patient population. Using IBM MarketScan databases,
investigators identified patients who received 10 kHz Therapy
between 2016 and 2019 and who had received a diabetes or diabetic
neuropathy diagnosis within two years before implantation. Cost
data were collected for the six months before receiving the 10 kHz
Therapy (baseline) and for the periods of one, three, and six
months post-implantation. The median total cost before receiving 10
kHz Therapy was $19,220 and was
$13,305 at six months
post-implantation. The median out-of-pocket cost before receiving
10 kHz Therapy was $1,477 and was
$710 at six months post-implantation.
The average total cost reduction from before to six months
post-implantation was $5,118 (P
< .001), or $853 per month.
Investigators concluded that 10 kHz Therapy significantly reduces
HCU in patients with PDN.
"These publications demonstrate that our therapy is not only
reshaping care for people with chronic pain but also reducing costs
for both patients and health systems," said Kevin Thornal, CEO and president of Nevro. "This
evidence underscores our commitment to producing highly effective,
data-backed therapies that are accessible to those who need them
most."
About Painful Diabetic Neuropathy (PDN)
The World
Health Organization estimates 422 million adults live with diabetes
worldwide and its prevalence (8.5%) has nearly doubled over four
decades.1 Diabetes may cause systemic damage with a
profound impact on health-related quality of life and is
potentially life-threatening. Diabetic peripheral neuropathy is a
common complication presenting as pain and other dysesthesias,
including numbness, burning, or tingling. Approximately 20% of
patients with diabetes will develop PDN, a progressive, potentially
debilitating chronic neuropathic pain
condition.2 In the U.S., it is estimated
that there are approximately 140,000 to 200,000 PDN patients each
year that are refractory to conventional medical management,
representing an annual total addressable market opportunity of
approximately $3.5 billion to
$5.0
billion.3,4
Internet Posting of Information
Nevro routinely posts
information that may be important to investors in the "Investor
Relations" section of its website at www.nevro.com. The company
encourages investors and potential investors to consult the Nevro
website regularly for important information about Nevro.
About Nevro
Headquartered in Redwood City, California, Nevro is a global
medical device company focused on delivering comprehensive,
life-changing solutions that continue to set the standard for
enduring patient outcomes in chronic pain treatment. The company
started with a simple mission to help more patients suffering from
debilitating pain and developed its proprietary 10 kHz Therapy™, an
evidence-based, non-pharmacologic innovation that has impacted the
lives of more than 100,000 patients globally. Nevro's comprehensive
HFX™ spinal cord stimulation (SCS) platform includes a
Senza™ SCS system and support services for the treatment of
chronic pain of the trunk and limb and painful diabetic
neuropathy.
Senza®, Senza II®, Senza Omnia™, and HFX iQ™ are the only SCS
systems that deliver Nevro's proprietary 10 kHz Therapy. Nevro's
unique support services provide every patient with an HFX Coach™
throughout their pain relief journey and every physician with HFX
Cloud™ insights for enhanced patient and practice management.
SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, 10 kHz
Therapy, HFX, the HFX logo, HFX iQ, the HFX iQ logo, HFX Algorithm,
HFX CONNECT, the HFX Connect logo, HFX ACCESS, the HFX Access logo,
HFX COACH, the HFX Coach logo, HFX CLOUD, the HFX Cloud logo,
RELIEF MULTIPLIED, the X logo, NEVRO, and the NEVRO logo are
trademarks or registered trademarks of Nevro Corp. Patents covering
Senza HFX iQ and other Nevro products are listed at
Nevro.com/patents.
To learn more about Nevro, connect with us
on LinkedIn, Twitter, Facebook, and Instagram.
*Senza HFX iQ™ uses a fixed set of instructions to provide
optimized treatment recommendations that utilize direct patient
input from assessments on pain and quality of life measures.
Forward-Looking Statements
In addition to historical
information, this press release contains forward-looking statements
reflecting the company's current beliefs and expectations of
management made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995, including: our
belief in the cost effectiveness of our 10 kHz Therapy for PDN and
NSBP patients; and our belief that this data demonstrates that our
therapy is not only reshaping care for people with chronic pain but
also reducing costs for both patients and health systems. These
forward-looking statements are based upon information that is
currently available to us or our current expectations, speak only
as of the date hereof, and are subject to numerous risks and
uncertainties, including our ability to successfully commercialize
our products; our ability to manufacture our products to meet
demand; the level and availability of third-party payor
reimbursement for our products; our ability to effectively manage
our anticipated growth and the costs and expenses of operating our
business; our ability to protect our intellectual property rights
and proprietary technologies; our ability to operate our business
without infringing the intellectual property rights and proprietary
technology of third parties; competition in our industry;
additional capital and credit availability; our ability to attract
and retain qualified personnel; and product liability claims. These
factors, together with those that are described in greater detail
in our Annual Report on Form 10-K filed on February 21, 2023, as well as any reports that we
may file with the Securities and Exchange Commission in the future,
may cause our actual results, performance or achievements to differ
materially and adversely from those anticipated or implied by our
forward-looking statements. We expressly disclaim any obligation,
except as required by law, or undertaking to update or revise any
such forward-looking statements.
Investors and Media:
Nevro Corp.
ir@nevro.com
1 World Health Organization.
(2016). Global report on diabetes. World Health Organization.
https://apps.who.int/iris/handle/10665/204871
2 Schmader K. E. (2002). Epidemiology
and impact on quality of life of postherpetic neuralgia and painful
diabetic neuropathy. The Clinical journal of pain, 18(6),
350–354.
3 CDC National Diabetes Statistics
Report 2020.
4 Trinity Partners Market Research
2017.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/new-data-demonstrate-the-health-economic-benefits-of-nevros-high-frequency-spinal-cord-stimulation-therapy-301930001.html
SOURCE Nevro Corp.